Feed HSDT
HS

Helius Medical Technologies, Inc.

HSDT · NASDAQ

$2.76 +17.45% (+$0.41)
1M +48.39%
Market Cap $133.7M
P/E Ratio -
Div. Yield -
ROE 122.85%
Piotroski F-Score Weak
3/9
Valuation
62 /100
Fair
P/B 0.81x
P/S 11.08x
PEG N/A
Growth
100 /100
Growing
Book val. growth 232.97%
Rev. growth 97.00%
FCF growth N/A
Profitability
0 /100
Weak
Op. margin 200.47%
Net margin 1,302.78%
FCF margin N/A
Quality
13 /100
Poor
ROA 89.33%
Asset turnover 0.07x
ROE 122.85%
Debt
100 /100
Low
Current ratio 13.31x
Debt/Assets N/A
Net debt/EBITDA N/A
Stability
56 /100
Moderate
Profitable years 0
EPS volatility 15.78%
Beta 1.07x

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre HSDT
Online

Despre companie

Helius Medical Technologies, Inc. is a biopharmaceutical company focused on the development and commercialization of neurostimulation therapies for the treatment of neurological disorders. Its main product platform is the Portable Neuromodulation Stimulator (PoNS) technology, which utilizes tongue stimulation to influence brain function and the nervous system. This technology has the potential to help patients with various neurological disorders, including traumatic brain injury, multiple sclerosis, and other neurological conditions. The company focuses on conducting clinical trials and obtaining regulatory approvals for its therapeutic products. Its goal is to provide innovative and effective treatment methods to improve the quality of life for patients suffering from neurological disorders. Shares of Helius Medical Technologies, Inc. may be an interesting investment opportunity for investors following the biopharmaceutical industry and neurological medicine.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Financial Services

Industry

Asset Management

CEO

Dane Carl Andreeff

Employees

21

Headquarters

Newtown

Evenimente viitoare

17 NOV.

Earnings

Upcoming earnings report

59d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.